Cargando…

MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

We retrospectively analyzed data from 197 patients with refractory or relapsed acute myeloid leukemia (r/rAML) who underwent allo‐HCT between January 2013 and February 2020 in our center (patients with promyelocytic leukemia were excluded). Of all patients, 86 achieved a complete morphological remis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hao, Qi, Liu, Xinyue, Zhang, Yongping, Zhang, Dongmei, Li, Boran, Wang, Jingbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529132/ https://www.ncbi.nlm.nih.gov/pubmed/34432318 http://dx.doi.org/10.1002/jcla.23974

Ejemplares similares

A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia
por: Wang, Jingbo, et al.
Publicado: (2018)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
por: Kayser, S, et al.
Publicado: (2016)

Cardiac Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
por: Facenda-Lorenzo, María, et al.
Publicado: (2016)

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
por: Maffini, Enrico, et al.
Publicado: (2022)

Extramedullary relapse of leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective study
por: Xie, Ning, et al.
Publicado: (2019)

Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Extramedullary Gastric Relapse of Acute Myeloid Leukemia After Allogenic Hematopoietic Stem Cell Transplantation
por: Hong, Ji-Yun, et al.
Publicado: (2020)

PB2183: RELAPSE PREDICTS POOR OUTCOMES IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Gavriilaki, E., et al.
Publicado: (2022)

Salvaged allogeneic hematopoietic stem cell transplantation for pediatric chemotherapy refractory acute leukemia
por: Wang, Jingbo, et al.
Publicado: (2017)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Antar, Ahmad I., et al.
Publicado: (2020)

Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion
por: Shen, Yuyan, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment
por: Hu, Guan-hua, et al.
Publicado: (2020)

Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Fuchs, Mary, et al.
Publicado: (2012)

Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning
por: Guo, Zhi, et al.
Publicado: (2017)

A case of tuberculosis meningitis after allogeneic hematopoietic stem cell transplantation for relapsed Acute Myeloid Leukemia
por: Yang, Jinyoung, et al.
Publicado: (2020)

P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION
por: Liang, Chen, et al.
Publicado: (2023)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

P1302: SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ALSO THE CURATIVE AND SAFE TREATMENT FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN THE ERA OF TARGETED THERAPY
Publicado: (2023)

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
por: Teich, Katrin, et al.
Publicado: (2023)

Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
por: Lipof, Jodi J., et al.
Publicado: (2018)

Correction: Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning
por: Guo, Zhi, et al.
Publicado: (2019)

Efficacy and safety of venetoclax in combination therapy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Yang, Fan, et al.
Publicado: (2021)

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response
por: Begna, K. H., et al.
Publicado: (2022)

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
por: Kantarjian, Hagop M., et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
por: Lee, Je-Hwan, et al.
Publicado: (2010)

P375: INOTUZUMB OZOGAMICIN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY ACUTE B-LYMPHOBLASTIC LEUKEMIA
por: Kayser, Sabine, et al.
Publicado: (2023)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
por: Feng, Yimei, et al.
Publicado: (2023)

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
por: Pagliuca, Simona, et al.
Publicado: (2023)

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
por: Pagliuca, Simona, et al.
Publicado: (2023)

Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Shi, Wei, et al.
Publicado: (2020)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
por: Kumode, Takahiro, et al.
Publicado: (2020)

Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution
por: Lin, Cheng-Hsien, et al.
Publicado: (2022)

Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
por: Lindahl, Hannes, et al.
Publicado: (2022)

P569: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PREGNANT WOMEN WITH ACUTE MYELOID LEUKEMIA
por: Troitskaya, Vera, et al.
Publicado: (2023)

PB2443: APPLICABILITY OF SHORT TANDEM REPEAT (STR) IN LEUKEMIA PATIENTS RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ERA OF MINIMAL RESIDUAL DISEASE (MRD)
por: Kim, Juhyung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h51egce7ii85mviliok864i0ah